Therapy Areas: Autoimmune
Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata
16 November 2018 - - US-based clinical stage biopharmaceutical company Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) has received interim topline results from the first two cohorts of its Phase 2a trial evaluating its investigational treatment CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss, the company said.

At 24 weeks, patients treated with an 8 mg twice-daily dose of CTP-543 met the primary efficacy endpoint vs. placebo (p
Login
Username:

Password: